The 24-Year Course of Symptomatic Disorders in Patients With Borderline Personality Disorder and Personality-Disordered Comparison Subjects: Description and Prediction of Recovery From BPD

Mary C. Zanarini, EdD ; Frances R. Frankenburg, MD ; Isabel V. Glass, BA ; Garrett M. Fitzmaurice, ScD

J Clin Psychiatry 2024;85(3):24m15370

Abstract

Objectives: Our first objective was to compare the prevalence of symptomatic disorders (formerly Axis I disorders) over 24 years of prospective follow-up among patients with borderline personality disorder (BPD) and other personality disordered comparison subjects as well as recovered vs nonrecovered borderline patients. Our second objective was to assess the relationship between the absence of 5 major classes of symptomatic disorders over time and the likelihood of concurrent recovery among borderline patients.

Methods: The McLean Study of Adult Development (MSAD) is a naturalistic prospective follow-up study of 362 inpatients assessed at 12 contiguous 2-year follow-up waves. Symptomatic disorders were assessed at each follow-up using the Structured Clinical Interview for DSM-III-R Axis I Disorders. Generalized estimating equations were used to assess all outcomes. Data were collected from June 1992 to December 2018.

Results: Patients with BPD had significantly higher rates of all 5 types of disorders studied than comparison subjects. However, the prevalence of these disorders declined significantly over time at similar rates for both study groups. This finding was similar for recovered and nonrecovered borderline patients. When the absence of these types of comorbid disorders was used to predict recovery status, substance use disorders were a substantially stronger predictor of recovery than the other 4 classes of disorders (relative risk ratio: 2.53, P < .001).

Conclusions: The results of this study suggest that symptomatic disorders co occur less commonly with BPD over time, particularly for recovered borderline patients. They also suggest that the absence of substance use disorders is the strongest predictor of achieving recovery from BPD.

J Clin Psychiatry 2024;85(3):24m15370

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (55)

Gunderson JG, Singer MT. Defining borderline patients: an overview. Am J Psychiatry. 1975;132(1):1–10. PubMed CrossRef
Zanarini MC, Gunderson JG, Frankenburg FR. Axis I phenomenology of borderline personality disorder. Compr Psychiatry. 1989;30(2):149–156. PubMed CrossRef
Oldham JM, Skodol AE, Kellman HD, et al. Comorbidity of axis I and axis II disorders. Am J Psychiatry. 1995;152(4):571–578. PubMed CrossRef
Zimmerman M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry. 1999;40(4):245–252. PubMed CrossRef
Grinker RR, Werble W, Drye RC. The Borderline Syndrome. Basic Books; 1968.
Werble B. Second follow-up study of borderline patients. Arch Gen Psychiatry. 1970;23(1):3–7. PubMed CrossRef
Gunderson JG, Carpenter WT Jr., Strauss JS. Borderline and schizophrenic patients: a comparative study. Am J Psychiatry. 1975;132(12):1257–1264. PubMed CrossRef
Carpenter WT Jr., Gunderson JG. Five year follow-up comparison of borderline and schizophrenic patients. Compr Psychiatry. 1977;18(6):567–571. PubMed CrossRef
Pope HG Jr., Jonas JM, Hudson JI, et al. The validity of DSM-III borderline personality disorder. A phenomenologic, family history, treatment response, and long-term follow-up study. Arch Gen Psychiatry. 1983;40(1):23–30. PubMed CrossRef
Akiskal HS, Chen SE, Davis GC, et al. Borderline: an adjective in search of a noun. J Clin Psychiatry. 1985;46(2):41–48. PubMed
Barasch A, Frances A, Hurt S, et al. Stability and distinctness of borderline personality disorder. Am J Psychiatry. 1985;142(12):1484–1486. PubMed CrossRef
Perry JC, Cooper SH. Psychodynamics, symptoms, and outcome in borderline and antisocial personality disorders and bipolar type II affective disorder. In: McGlashan TH, ed. The Borderline: Current Empirical Research. American Psychiatric Press; 1985:19–41.
Nace EP, Saxon JJ Jr., Shore N. Borderline personality disorder and alcoholism treatment: a one-year follow-up study. J Stud Alcohol. 1986;47(3):196–200. PubMed CrossRef
Tucker L, Bauer SF, Wagner S, et al. Long-term hospital treatment of borderline patients: a descriptive outcome study. Am J Psychiatry. 1987;144(11):1443–1448. PubMed CrossRef
Modestin J, Villiger C. Follow-up study on borderline versus nonborderline personality disorders. Compr Psychiatry. 1989;30(3):236–244. PubMed CrossRef
Links PS, Mitton JE, Steiner M. Predicting outcome for borderline personality disorder. Compr Psychiatry. 1990;31(6):490–498. PubMed CrossRef
Links PS, Heslegrave RJ, Mitton JE, et al. Borderline psychopathology and recurrences of clinical disorders. J Nerv Ment Dis. 1995;183(9):582–586. PubMed CrossRef
Mehlum L, Friis S, Irion T, et al. Personality disorders 2–5 years after treatment: a prospective follow-up study. Acta Psychiatr Scand. 1991;84(1):72–77. PubMed CrossRef
Stevenson J, Meares R. An outcome study of psychotherapy for patients with borderline personality disorder. Am J Psychiatry. 1992;149(3):358–362. PubMed CrossRef
Linehan MM, Heard HL, Armstrong HE. Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Arch Gen Psychiatry. 1993;50(12):971–974. PubMed CrossRef
Sandell R, Alfredsson E, Berg M, et al. Clinical significance of outcome in long term follow-up of borderline patients at a day hospital. Acta Psychiatr Scand. 1993;87(6):405–413. PubMed CrossRef
Antikainen R, Hintikka J, Lehtonen J, et al. A prospective three-year follow-up study of borderline personality disorder inpatients. Acta Psychiatr Scand. 1995;92(5):327–335. PubMed CrossRef
Najavits LM, Gunderson JG. Better than expected: improvements in borderline personality disorder in a 3-year prospective outcome study. Compr Psychiatry. 1995;36(4):296–302. PubMed CrossRef
Senol S, Dereboy C, Yüksel N. Borderline disorder in Turkey: a 2- to 4-year follow up. Soc Psychiatry Psychiatr Epidemiol. 1997;32(2):109–112. PubMed CrossRef
Plakun EM, Burkhardt PE, Muller JP. 14-year follow-up of borderline and schizotypal personality disorders. Compr Psychiatry. 1985;26(5):448–455. PubMed CrossRef
McGlashan TH. The Chestnut Lodge follow-up study. III. Long-term outcome of borderline personalities. Arch Gen Psychiatry. 1986;43(1):20–30. PubMed CrossRef
Paris J, Brown R, Nowlis D. Long-term follow-up of borderline patients in a general hospital. Compr Psychiatry. 1987;28(6):530–535. PubMed CrossRef
Stone MH. The Fate of Borderline Patients. Guilford Press; 1990.
Paris J, Zweig-Frank H. A 27-year follow-up of patients with borderline personality disorder. Compr Psychiatry. 2001;42(6):482–487. PubMed CrossRef
Zanarini MC, Frankenburg FR, Hennen J, et al. The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up. J Pers Disord. 2005;19(5):505–523. PubMed CrossRef
Skodol AE, Gunderson JG, Shea MT, et al. The collaborative longitudinal personality disorders study (CLPS): overview and implications. J Pers Disord. 2005;19(5):487–504. PubMed CrossRef
Temes CM, Frankenburg FR, Fitzmaurice GM, et al. Deaths by suicide and other causes among patients with borderline personality disorder and personality disordered comparison subjects over 24 years of prospective follow-up. J Clin Psychiatry. 2019;80(1):18m12436. PubMed CrossRef
Gunderson JG, Stout RL, McGlashan TH, et al. Ten-year course of borderline personality disorder: psychopathology and function from the collaborative longitudinal personality disorders study. Arch Gen Psychiatry. 2011;68(8):827–837. PubMed CrossRef
Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry. 1998;155(12):1733–1739. PubMed CrossRef
McGlashan TH, Grilo CM, Skodol AE, et al. The collaborative longitudinal personality disorders study: baseline Axis I/II and II/II diagnostic co-occurrence. Acta Psychiatr Scand. 2000;102(4):256–264. PubMed CrossRef
Zanarini MC, Frankenburg FR, Hennen J, et al. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry. 2004;161(11):2108–2114. PubMed CrossRef
Shea MT, Stout RL, Yen S, et al. Associations in the course of personality disorders and axis I disorders over time. J Abnorm Psychol. 2004;113(4):499–508. PubMed CrossRef
Zanarini MC, Frankenburg FR, Hennen J, et al. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry. 2003;160(2):274–283. PubMed CrossRef
Spitzer RL, Williams JB, Gibbon M, et al. The structured clinical interview for DSM III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624–629. PubMed CrossRef
Zanarini MC, Gunderson JG, Frankenburg FR, et al. The revised diagnostic interview for borderlines: discriminating BPD from other Axis II disorders. J Personal Disord. 1989;3(1):10–18.
Zanarini MC, Frankenburg FR, Chauncey DL, et al. The diagnostic interview for personality disorders: interrater and test-retest reliability. Compr Psychiatry. 1987;28(6):467–480. PubMed CrossRef
Zanarini MC, Frankenburg FR. Attainment and maintenance of reliability of axis I and II disorders over the course of a longitudinal study. Compr Psychiatry. 2001;42(5):369–374. PubMed CrossRef
Zanarini MC, Frankenburg FR, Vujanovic AA. Inter-rater and test-retest reliability of the revised diagnostic interview for borderlines. J Pers Disord. 2002;16(3):270–276. PubMed CrossRef
Hollingshead AB. Two factor index of social position. Yale University; 1957.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd rev ed. American Psychiatric Association; 1987:32.
Zanarini MC, Frankenburg FR, Reich DB, et al. Treatment rates for patients with borderline personality disorder and other personality disorders: a 16-year study. Psychiatr Serv. 2015;66(1):15–20. PubMed CrossRef
Zanarini MC, Frankenburg FR, Bradford Reich D, et al. Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 Years of prospective follow-up. J Clin Psychopharmacol. 2015;35(1):63–67. PubMed CrossRef
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.
Zanarini MC, Frankenburg FR, Reich DB, et al. Fluidity of the subsyndromal phenomenology of borderline personality disorder over 16 years of prospective follow-up. Am J Psychiatry. 2016;173(7):688–694. PubMed CrossRef
Zanarini MC, Hörz S, Frankenburg FR, et al. The 10-year course of PTSD in borderline patients and axis II comparison subjects. Acta Psychiatr Scand. 2011;124(5):349–356. PubMed CrossRef
Lee NK, Cameron J, Jenner L. A systematic review of interventions for co occurring substance use and borderline personality disorders. Drug Alcohol Rev. 2015;34(6):663–672. PubMed CrossRef
Linehan MM, Schmidt H 3rd, Dimeff LA, et al. Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict. 1999;8(4):279–292. PubMed CrossRef
Linehan MM, Dimeff LA, Reynolds SK, et al. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend. 2002;67(1):13–26. PubMed CrossRef
Reus VI, Fochtmann LJ, Bukstein O, et al. The American psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86–90. PubMed
Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760–1772. PubMed CrossRef